Shots:
- Novatim has entered into an exclusive global licensing agreement (excl. China) with RADIANCE Biopharma for KY-0301 to treat cancer
- As per the deal, RADIANCE Biopharma will receive rights to develop, register, & commercialize KY-0301 globally (excl. China) in exchange for $15M upfront, ~$150M in R&D & registration milestones & ~$1B in commercial milestone, with progressive sales commissions based on annual net sales
- KY-0301 is a nano-bispecific ADC, which received US FDA’s IND approval in 2024 & is being evaluated in P-I trials across China, showing superior tumor penetration, anti-tumor activity, & safety
Ref: Weixin| Image: Novatim & RADIANCE Biopharma | Press Release
Related News:- Arrowhead Enters a ~$2.2B Deal with Novartis for ARO-SNCA and TRiM-Based Therapies to Treat Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
